| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d21cbff64022f95c237c0bd3ec8656ca
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cc64a0225ee1b588c1d7af77250eee01 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1611
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate |
2018-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08aa28a8a6a854ee175bc1b488060364
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5fdcc9da4c22e2a8c65b3a27436fd78d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f9c6278690a1a93750e5b1e31e6769f2 |
| publicationDate |
2019-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2019028457-A2 |
| titleOfInvention |
FORMULATION OF NANOSUSPENSION OF DIETHYLSTILBESTROL INJECTABLE |
| abstract |
In certain embodiments, the present disclosure relates to cancer treatment formulations comprising a diethylstilbestrol (DES) charged particle and a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier can also be loaded into the particle. The formulations may also include a stabilizer which is also loaded into the particle. The particles can be dispersed in an aqueous solution to form a nanosuspension which is amenable to subcutaneous administration and sustained release of DES. Other embodiments relate to methods of treating cancer in a subject by administering a formulation according to the present disclosure. The subject may be a human subject suffering from prostate cancer. Administration of formulations to the subject may circumvent or minimize first pass metabolism. Administration may also minimize hepatic exposure of DES. Other embodiments relate to methods of preparing the formulations according to the present disclosure by loading a particle with DES. |
| priorityDate |
2017-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |